Molindone

  • (+/-)-Molindone
  • 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one
  • 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one
Formula
C16H24N2O2
Structure
Description
Crystals.
Uses
Medication.

Registry Numbers and Inventories.
CAS
7416-34-4
RTECS
NM3300000
RTECS class
Drug; Human Data
Merck
12,6315
Beilstein/Gmelin
413239

Properties.
Formula
C16H24N2O2
Formula mass
276.38
Melting point, °C
180 - 181
Solubility in water
Insoluble
pKa/pKb
6.83 (pKa)

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Hyperpyrexia, abnormally low blood pressure and shallow, rapid respirations have occurred with therapeutic use in patients previously exposed to neuroleptics. neuroleptic malignant syndrome (symptoms include: fever, rigidity, autonomic instability, altered mental status, rhabdomyolysis and diaphoresis) has been reported in one therapeutically dosed patient previously exposed to neuroleptics. Extrapyramidal effects (rigidity, tremor, akathisia, major tonic spasms and tardive dyskinesia) have been reported with therapeutic use and may occur in overdose.
   Ingestion
Dry mouth, contributing to dysphagia, has been reported during molindone therapy. Weight gain and loss during therapeutic use have occurred.
   Inhalation
Tachypnea occurred in a patient with neuroleptic malignant syndrome previously exposed to other neuroleptics.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.